Article Contents ::
- 1 The Brand Name BETNOVATE-S Has Generic Salt :: Betamethasone
- 2 BETNOVATE-S Is From Company Gsk Priced :: Rs. 20.29
- 3 BETNOVATE-S have Betamethasone is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name BETNOVATE-S Has Generic Salt :: Betamethasone
BETNOVATE-S Is From Company Gsk Priced :: Rs. 20.29
BETNOVATE-S have Betamethasone is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 20G|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Gsk :: BETNOVATE-S||Betamethasone||#N/A||#N/A|
Indications for Drugs ::
Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Lichen planus, Psoriasis, Asthma, Eczema, Contact dermatitis, Multiple sclerosis, Drug hypersensitivity reactions, Perennial or seasonal allergic rhinitis, Serum sickness, Transfusion reactions, Severe erythema multiforme (Stevens-Johnson syndrome), Leukemias, Lymphomas, Acute gouty arthritis, Acute rheumatic carditis, Psoriatic arthritis, Including juvenile rheumatoid arthritis, Dermatomyositis, Polymyositis, Systemic lupus erythematosus, Psoriatic plaques, Allergic and inflammatory disorders, Congenital adrenal hyperplasia
Drug Dose ::
Oral Allergic and inflammatory disorders Adult: 0.5-5 mg daily. Child: For inflammatory conditions: >12 yr: 0.0175-0.125 mg base/kg daily, dose may be divided every 6-12 hr.
Hypersensitivity; systemic fungal or acute infections.
Drug Precautions ::
Uncontrolled diabetes, peptic ulcer, osteoporosis, psychosis, psychoneurosis, pregnancy and lactation. Congestive heart failure, hypertension, epilepsy, CRF, elderly, regular monitoring of patients on long term therapy, withdraw gradually, glaucoma, hypothyroidism, cirrhosis, ocular herpes simplex, ulcerative colitis, infants and children.
Drug Side Effects ::
Sodium and fluid retention, potassium and calcium depletion. Muscle wasting, weakness, osteoporosis. GI disturbances and bleeding. Increased appetite and delayed wound healing; hirsutism, bruising, striae, acne; raised intracranial pressure, headache, depression, psychosis, menstrual irregularities. Hyperglycaemia, DM. Suppression of pituitary-adrenocortical axis. Growth retardation in children (prolonged therapy). Increased susceptibility for infections. Topical use: Dermal atrophy, local irritation, folliculitis, hypertrichosis. Inhalation: Hoarseness, candidiasis of mouth and throat. Topical application to the eye: Corneal ulcers, raised IOP and reduced visual acuity. Intradermal injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis, esp in load bearing joints. Potentially Fatal: Abrupt withdrawal leading to acute adrenal insufficiency manifesting as malaise, weakness, mental changes, muscle and joint pains, dystonia, hypoglycaemia, hypotension, dehydration and death. Rapid IV inj may cause CV collapse.
Pregnancy category ::
Drug Mode of Action ::
Betamethasone is a corticosteroid with mainly glucocorticoid activity. It prevents and controls inflammation by controlling the rate of protein synthesis, depressing the migration of polymorphonuclear leukocytes and fibroblasts, and reversing capillary permeability and lysosomal stabilisation.
Drug Interactions ::
Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Potentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.